Pharmacokinetics of E-5-(2-bromovinyl)-2'-deoxyuridine in mice.
The pharmacokinetics of the newly developed anti-herpes agent, E-5-(2-bromovinyl)-2'-deoxyuridine, was compared with that of the standard anti-herpes drug 5-iodo-2'-deoxyuridine. Both compounds were administered to mice at 100 mg/kg by either the intraperitoneal, subcutaneous, or oral route. The active blood drug levels achieved by E-5-(2-bromovinyl)-2'-deoxyuridine were considerably higher than those attained by 5-iodo-2'-deoxyuridine (serum peak concentrations: 40 to 100 and 4 to 10 mug/ml, respectively). Active blood drug levels could still be found 320 min after oral administration of E-5-(2-bromovinyl)-2'-deoxyuridine.
D000818:Animals; D000998:Antiviral Agents; D001923:Brain Chemistry; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives; D005467:Floxuridine / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D007065:Idoxuridine / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000032:analysis; D008168:Lung / Q000032:analysis; D051379:Mice; D018139:Simplexvirus
D000998:Antiviral Agents; D005467:Floxuridine; C020235:brivudine; D001973:Bromodeoxyuridine; D007065:Idoxuridine